Gadobutrol Exerts a Cytogenotoxic Effect in SH-SY5Y Neuroblastoma Cells

Batuhan Bilgin; Mehmet Tahir Husunet

doi:10.58600/eurjther2576

Authors

Batuhan Bilgin Department of Biophysics, Gaziantep Islam Science and Technology University Faculty of Medicine, Gaziantep, Türkiye https://orcid.org/0000-0002-3470-1783
Mehmet Tahir Husunet Department of Medical Genetics, Gaziantep Islam Science and Technology University Faculty of Medicine, Gaziantep, Türkiye https://orcid.org/0000-0003-1424-5132

DOI:

https://doi.org/10.58600/eurjther2576

Keywords:

Neuroblastoma, Gadobutrol, cytotoxicity, Genotoxicity, SH-SY5Y cell

Abstract

Objective: Gadobutrol is a macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI). Although it is also used in the imaging of malignant tumors, its effect on SH-SY5Y neuroblastoma cells remains unclear. The aim of this study was to investigate the effects of gadobutol on cytotoxicity and genotoxicity in SH-SY5Y neuroblastoma cells.

Methods: After incubation of neuroblastoma cells with gadobutrol (0.1 mM, 1 mM, 10 mM, and 100 mM), cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. After determining the IC 50 value of gadobutrol, the genotoxicity effect of gadobutrol (1.75 mM, 3.50 mM, and 7 mM) on neuroblastoma cells was examined by Comet assay.

Results: Gadobutrol (0.1 mM, 1 mM, 10 mM, and 100 mM) statistically significantly decreased cell viability in SH-SY5Y neuroblastoma cells (p < 0.0001, p < 0.0001, p < 0.0001 and p < 0.0001, respectively). Gadobutrol (1.75 mM, 3.50 mM, and 7 mM) caused an increase in genotoxicity in neuroblastoma cells. However, gadobutrol (3.50 mM) and gadobutrol (7 mM) statistically significantly increased genotoxicity in neuroblastoma cells (p < 0.05 and p < 0.01, respectively).

Conclusion: The results of this in vitro study show that gadobutrol used as a contrast agent in MRI increases both cytotoxicity and genotoxicity in SH-SY5Y neuroblastoma cells. The cytogenotoxic effect of gadobutrol in SH-SY5Y neuroblastoma cells may point to it as a promising new strategy for the treatment of neuroblastoma.

Metrics

Metrics Loading ...

References

Olgun HN, Arayici ME, Cecen RE, Basbinar Y, Ellidokuz H (2023) The association between birth weight and the risk of neuroblastoma: a meta-analysis of observational studies involving 4,361,141 participants. Am J Cancer Res. 13(9):3854-3863. https://doi.org/10.21203/rs.3.rs-2483109/v1

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma. Nat Rev Dis Primers. 2:16078. https://doi.org/10.1038/nrdp.2016.78

Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203-216. https://doi.org/10.1038/nrc1014

Wieczorek A, Zaniewska-Tekieli A, Ehlert K, Pawinska-Wasikowska K, Balwierz W, Lode H (2023) Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma. Front Oncol. 13:1082771. https://doi.org/10.3389/fonc.2023.1082771

Endrikat J, Gutberlet M, Barkhausen J, Schöckel L, Bhatti A, Harz C, Hoffmann KT (2024) Clinical Efficacy of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations. Invest Radiol. 59(5):345-358. https://doi.org/10.1097/rli.0000000000001041

Scott LJ (2013) Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin Drug Investig. 33(4):303–314. https://doi.org/10.1007/s40261-013-0066-0

Carver PL (2019) Metals in Medicine: The Therapeutic Use of Metal Ions in the Clinic. Met Ions Life Sci. 19. https://doi.org/10.1515/9783110527872-007

Robertson AG, Rendina LM (2021) Gadolinium theranostics for the diagnosis and treatment of cancer. Chem Soc Rev. 50(7):4231-4244. https://doi.org/10.1039/d0cs01075h

Erdoğan MA, Apaydin M, Armagan G, Taskiran D (2021) Evaluation of toxicity of gadolinium-based contrast agents on neuronal cells. Acta Radiol. 62(2):206-214. https://doi.org/10.1177/0284185120920801

Kebriaezadeh A, Ashrafi S, Rasouli R, Ebrahimi SES, Hamedani MP, Assadi A, Saffari M, Ardestani MS (2016) Gadobutrol-dendrimer effects on metastatic and apoptotic gene expression. Advances in nano research. 4(2):145. https://doi.org/10.12989/anr.2016.4.2.145

Bilgin B, Adam M, Hekim MG, Bulut F, Ozcan M (2024) Gadolinium-based contrast agents aggravate mechanical and thermal hyperalgesia in a nitroglycerine-induced migraine model in male mice. Magn Reson Imaging. 111:67-73. https://doi.org/10.1016/j.mri.2024.04.007

Boyken J, Lohrke J, Treu A, Neddens J, Jost G, Ulbrich HF, Balzer T, Frenzel T, Prokesch M, Thuss U, Pietsch H (2024) Gadolinium Presence in Rat Skin: Assessment of Histopathologic Changes Associated with Small Fiber Neuropathy. Radiology. 310(1):e231984. https://doi.org/10.1148/radiol.231984

Ünlü I, Tuncer MC, Özdemir I (2025) Exploring apoptotic pathways in SH-SY5Y neuroblastoma cells: combined effects of napabucasin and doxorubicin. Folia Morphol (Warsz). 10.5603/fm.103887. https://doi.org/10.5603/fm.103887

Wang K, Li Y, Wang L (2024) Chaetocin inhibits the progression of neuroblastoma by targeting JAK2/STAT3 signaling pathway in SH-SY5Y cells. Naunyn Schmiedebergs Arch Pharmacol. https://doi.org/10.1007/s00210-024-03426-8

Coimbra S, Rocha S, Sousa NR, Catarino C, Belo L, Bronze-da-Rocha E, Valente MJ, Santos-Silva A (2024) Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review. Int J Mol Sci. 25(7):4071. https://doi.org/10.3390/ijms25074071

Friebe B, Godenschweger F, Fatahi M, Speck O, Roggenbuck D, Reinhold D, Reddig A (2018) The potential toxic impact of different gadolinium-based contrast agents combined with 7-T MRI on isolated human lymphocytes. Eur Radiol Exp. 2(1):40. https://doi.org/10.1186/s41747-018-0069-y

Gallorini M, Cataldi A, di Giacomo V (2014) HEMA-induced cytotoxicity: oxidative stress, genotoxicity and apoptosis. Int Endod J. 47(9):813-818. https://doi.org/10.1111/iej.12232

Zhu X, Wu J, Chen X, Shi D, Hui P, Wang H, Wu Z, Wu S, Bao W, Fan H (2024) DNA ligase III mediates deoxynivalenol exposure-induced DNA damage in intestinal epithelial cells by regulating oxidative stress and interaction with PCNA. Int J Biol Macromol. 282:137137. https://doi.org/10.1016/j.ijbiomac.2024.137137

Bostanci A, Doganlar O (2024) Melatonin enhances temozolomide-induced apoptosis in glioblastoma and neuroblastoma cells. Exp Oncol. 46(2):87-100. https://doi.org/10.15407/exp-oncology.2024.02.087

Qi Z, Wang X, Yin L, Ma K, Chen L, Li J (2022) Effects of Surgery Combined with Different Chemotherapy on Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-1 in Children with Neuroblastoma. J Oncol. 2022:8319221. https://doi.org/10.1155/2022/8319221

Mahmood F, Nielsen UG, Jørgensen CB, Brink C, Thomsen HS, Hansen RH (2022) Safety of gadolinium based contrast agents in magnetic resonance imaging-guided radiotherapy - An investigation of chelate stability using relaxometry. Phys Imaging Radiat Oncol. 21:96-100. https://doi.org/10.1016/j.phro.2022.02.015

Baykara M, Ozcan M, Bilgen M, Kelestimur H (2019) Effects of gadolinium and gadolinium chelates on intracellular calcium signaling in sensory neurons. Neurosci Lett. 707:134295. https://doi.org/10.1016/j.neulet.2019.134295

Adam M, Ozcan S, Dalkilic S, Tektemur NK, Tekin S, Bilgin B, Hekim MG, Bulut F, Kelestemur MM, Canpolat S, Ozcan M (2023) Modulation of Neuronal Damage in DRG by Asprosin in a High-Glucose Environment and Its Impact on miRNA181-a Expression in Diabetic DRG. Neurotox Res. 42(1):5. https://doi.org/10.1007/s12640-023-00678-9

Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 175(1):184-191. https://doi.org/10.1016/0014-4827(88)90265-0

Lu ZR, Laney V, Li Y (2022) Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer. Acc Chem Res. 55(19):2833-2847. https://doi.org/10.1021/acs.accounts.2c00346

Wamelink I, Azizova A, Booth TC, Mutsaerts H, Ogunleye A, Mankad K, Petr J, Barkhof F, Keil VC (2024) Brain Tumor Imaging without Gadolinium-based Contrast Agents: Feasible or Fantasy? Radiology. 310(2):e230793. https://doi.org/10.1148/radiol.230793

Magda D, Miller RA (2006) Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol. 16(6):466-476. https://doi.org/10.1016/j.semcancer.2006.09.002

Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, Crémillieux Y, Fries P, Coll JL, Rodriguez-Lafrasse C, Janier M, Dutreix M, Barberi-Heyob M, Boschetti F, Denat F, Louis C, Porcel E, Lacombe S, Le Duc G, Deutsch E, Perfettini JL, Detappe A, Verry C, Berbeco R, Butterworth KT, McMahon SJ, Prise KM, Perriat P, Tillement O (2014) The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol. 87(1041):20140134. https://doi.org/10.1259/bjr.20140134

Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H (2017) Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Invest Radiol. 52(6):324-333. https://doi.org/10.1097/rli.0000000000000344

Huang XX, Jiang RH, Xu XQ, Zu QQ, Wu FY, Liu S, Shi HB (2021) Ischemic Stroke Increased Gadolinium Deposition in the Brain and Aggravated Astrocyte Injury After Gadolinium-Based Contrast Agent Administration: Linear Versus Macrocyclic Agents. J Magn Reson Imaging. 53(4):1282-1292. https://doi.org/10.1002/jmri.27407

Smith V, Foster J (2018) High-Risk Neuroblastoma Treatment Review. Children (Basel) 5(9):114. https://doi.org/10.3390/children5090114

Cohn S (2011) Advances in the treatment of neuroblastoma. Clin Adv Hematol Oncol. 9(11):865-867.

Castleberry RP (1997) Biology and treatment of neuroblastoma. Pediatr Clin North Am 44(4):919-937. https://doi.org/10.1016/s0031-3955(05)70537-x

Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 7(10):2958-2970.

Funke SKI, Factor C, Rasschaert M, Lezius L, Sperling M, Karst U, Robert P (2022) Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide. Radiology. 305(1):179-189. https://doi.org/10.1148/radiol.212600

Wack C, Steger-Hartmann T, Mylecraine L, Hofmeister R (2012) Toxicological safety evaluation of gadobutrol. Invest Radiol. 47(11):611-623. https://doi.org/10.1097/RLI.0b013e318263f128

Drew Y, Zenke FT, Curtin NJ (2024) DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat Rev Drug Discov. 24(1):19-39 https://doi.org/10.1038/s41573-024-01060-w

Pui CH, Relling MV (2004) Can the genotoxicity of chemotherapy be predicted? Lancet. 364(9438):917-918. https://doi.org/10.1016/s0140-6736(04)17038-4

Singh J, Carlisle DL, Pritchard DE, Patierno SR (1998) Chromium-induced genotoxicity and apoptosis: relationship to chromium carcinogenesis (review). Oncol Rep. 5(6):1307-1318. https://doi.org/10.3892/or.5.6.1307

Richeux F, Cascante M, Ennamany R, Saboureau D, Creppy EE (1999) Cytotoxicity and genotoxicity of capsaicin in human neuroblastoma cells SHSY-5Y. Arch Toxicol. 73(7):403-409. https://doi.org/10.1007/s002040050680

Akbas E, Unal F, Yuzbasioglu D (2022) Genotoxic effects of gadobutrol and gadoversetamide active substances used in magnetic resonance imaging in human peripheral lymphocytes in vitro. Drug Chem Toxicol. 45(6):2471-2482. https://doi.org/10.1080/01480545.2021.1957913

Cobanoglu H (2022) Assessment of genetic damage induced by gadolinium-based radiocontrast agents. J Trace Elem Med Biol. 70:126914. https://doi.org/10.1016/j.jtemb.2021.126914

Solmaz V, Köse Özlece H, Fatih Bozkurt M, Özkul B, Erbaş O (2021) Repeated gadoteric acid and gadobutrol exposure causes deterioration of behavior and memory functions in rats: MRI, histopathological and biochemical evidence. Brain Res. 1754:147256. https://doi.org/10.1016/j.brainres.2020.147256

Maecker HT, Wang W, Rosenberg-Hasson Y, Semelka RC, Hickey J, Koran LM (2020) An initial investigation of serum cytokine levels in patients with gadolinium retention. Radiol Bras. 53(5):306-313. https://doi.org/10.1590/0100-3984.2019.0075